B of A Securities Downgrades LianBio: Here's What You Need To Know

B of A Securities downgraded its rating of LianBio LIAN to Underperform with a price target of $3.00, changing its price target from $5.00 to $3.00.

Shares of LianBio are trading down 1.83% over the last 24 hours, at $4.29 per share.

A move to $3.00 would account for a 30.07% decrease from the current share price.

About LianBio

LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.